
|Videos|December 23, 2020
Moving Forward in the Management of Acute GvHD
Author(s)Targeted Oncology
Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































